Group items tagged

Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men. NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over 40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes could be prevented this year thanks to the high street checks." "The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added. Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart attacks and strokes each month.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

As Know Your Numbers! Week (2-8 September) kicks off, the NHS England is encouraging people in the East Midlands to get their blood pressure checked to prevent heart attacks and strokes. The residents can get their blood pressure checked at several places, including their local pharmacies. The initiative, part of a global campaign, highlights the crucial role of monitoring blood pressure, especially for those aged 40 and over. It is recommended that all adults aged 40 or over have their blood pressure tested at least every five years. High blood pressure or hypertension affects about a third of adults in the UK and is a major risk factor for cardiovascular disease (CVD), which is one of the leading causes of death in England. This condition often has no noticeable symptoms, but if untreated, it can result in serious health problems such as heart attacks and strokes. Local pharmacies play a crucial role in this health campaign, enabling individuals to monitor their risk of cardiovascular disease without needing an appointment. The NHS community pharmacy blood pressure check service has delivered more than a million checks nationally in the past year.

Community pharmacies are well placed to play a role in preventing deaths from cardiovascular disease (CVD) said Director of NHS Services. The recent analysis by the British Heart Foundation (BHF) revealed that nearly 100,000 more people with cardiovascular disease than expected have died since the start of the pandemic in England. Latest figures show that the number of people waiting for time-sensitive cardiac care was at a record high of nearly 390,000 at the end of April in England. Average ambulance response times for heart attacks and strokes have consistently been above 30 minutes since the beginning of 2022, and in December 2022 they even breached 90 minutes. The target is 18 minutes, though the Government has set a new average target of 30 minutes over 2023/24. Director of NHS Services, Alastair Buxton, said: "It is concerning to hear that there have been tens of thousands of preventable deaths from cardiovascular disease (CVD) since the start of the COVID-19 pandemic. We share BHF's desire to see more action on preventing the causes of CVD and, subject to appropriate funding being in place, community pharmacy teams are well placed to play a role in this.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

The National Health Service (NHS) on Monday launched a new national campaign to find the 'missing millions' who could be living with undiagnosed high blood pressure, often described as a 'silent killer'. People are being warned that the condition rarely has any symptoms and it can lead to fatal heart attacks, strokes, kidney disease and vascular dementia, if left untreated. According to the NHS, high blood pressure affects an estimated 32 per cent of adults and approximately three in 10 of these remain undiagnosed, equating to 4.2 million people in England. The NHS has expanded blood pressure checks in community pharmacies to include 2.5 million more tests as part of the Pharmacy First programme. With the 'Get Your Blood Pressure Checked' campaign, the health service is encouraging those aged 40 years and over to get a free blood pressure test at a participating pharmacy, for which they don't need to be booked in advance. Health Minister Andrea Leadsom expressed confidence that this new drive will help to prevent the potentially "fatal consequences" of untreated high blood pressure. She urged people to go to their local pharmacy to get their blood pressure checked, stating that it could be a "lifesaving trip."

Diabetes is recognised as a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to World Health Oragnization (WHO), more than 95 per cent of people with diabetes have type 2 diabetes, which is often preventable. In the UK, there are over 3 million cases of diabetes and a staggering 10 per cent of the NHS budget is spent on diabetes, with 90 per cent of this allocated to treating type 2 diabetes. Kavita Sharma, a clinical pharmacist specialising in diabetes and founder of Desi Diabetes, warns that the number of type 2 diabetes diagnoses is increasing each year, along with the rising prevalence of pre-diabetes. The pharmacist highlights that type 2 diabetes can be prevented through lifestyle changes, such as adopting a healthy diet, maintaining a healthy weight, and incorporating regular physical activity into daily life.

A new report from the Company Chemists' Association (CCA) is calling on NHS England to commission a community pharmacy-based national Type 2 diabetes screening service, which could save the NHS £50m each year. The CCA report, titled 'Increasing Access to Diabetes Screening and Prevention Through Community Pharmacy', highlights the urgent need for a national patient pathway for diabetes detection and management. It outlines how NHS-commissioned diabetes screening in community pharmacies across England could deliver numerous health benefits each year, including: Screening 1.5 million adults and identifying 180,000 prediabetics; Detecting 45,000 undiagnosed cases of diabetes and preventing them from developing serious complications Preventing nearly 7,000 heart attacks and strokes, and thus improving patients' quality of life Avoiding severe sight loss in around 15,000 people over their lifetime Saving the NHS £50 million annually by reducing diabetes-related costs. Type 2 diabetes and its complications are currently estimated to account for 10 per cent of the NHS annual budget, and this figure is projected to rise to 17 per cent by 2035/36.

The journey for patients to quit smoking can be challenging, but with the right strategies and support, it is achievable. Smoking cessation is a critical step for patients towards improving overall health and well-being. We caught up with Thorrun Govind, pharmacist, TV health expert and pharmacy lawyer at Brabners for her top tips. Govind notes that smoking is a leading cause of preventable diseases and deaths worldwide. It is associated with numerous health issues, including lung cancer, heart disease, stroke, and chronic obstructive pulmonary disease (COPD). Quitting smoking can significantly reduce the risk of these conditions and improve quality of life. Within weeks of quitting, individuals often experience improved lung function, better circulation, and enhanced sense of taste and smell. Govind advises that; After 20 minutes of quitting your pulse rate, will already be starting to return to normal. After 48 hours of quitting your carbon monoxide levels have dropped to that of a non-smoker. Your lungs are clearing out mucus and your senses of taste and smell are improving. After 1 year your risk of heart attack will have halved compared with a smoker's. This piece explores the various methods and benefits of smoking cessation.

Community pharmacies will be able to deliver approximately 15 million blood pressure screenings by 2026, revealed the Company Chemists' Association (CCA)'s new research. This will also prevent 15,000 people from suffering heart attacks or strokes. CCA has called the Government to take up their offer and commission pharmacies as the first port of call for cardiovascular care. "Thousands of lives can be saved with ambitious commissioning and the investment to match," said CCA. There is an opportunity to use the expertise of community pharmacy to go further and provide the care these newly identified patients' need. To do this the sector needs funding and workforce. The association said: "Community pharmacy is under great financial pressure, suffering a real term funding cut of over 30% over 8 years. With funding, the sector can transform to deliver this critical need for patients. Whilst there are plans to train Independent Prescribers (IPs), there are no clear roles for them to use these skills. There is a need to accelerate training plans to allow pharmacists to deliver the service described here and play their part in CVD management."

Beetroots are edible taproots that are reddish-purple in color. They are also known by other names such as garden beet, red beet and table beet. This vegetable is one of the healthiest ones because it is rich in various nutrients, including vitamins A, B6 and C, iron, magnesium, potassium and nitrate. You can add raw beetroot in salads or cook it with its peel so that all the nutrients that it contains are retained. Making this delicious vegetable a part of your diet is important as there are many beetroot benefits for health. 25 Benefits Of Beetroot For Skin, Hair And Health Here are 25 of the health benefits of beetroot: 1. Prevents Heart attack and stroke: